Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of TQB2825 in CD20 Positive Hematological Tumors
NCT05489276Phase 1Unknown
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Mar 2022
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tqb2825 in hematologic neoplasms, lymphoma, leukemia and 1 more, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose limiting toxicity at 104 weeks, Maximum tolerated dose at 104 weeks and 1 more. Status: unknown.
02
Drugs
tqb2825
03
Conditions
hematologic neoplasmslymphomaleukemiamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT05489276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489276.